BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 08, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ABT-333: Phase II started

Abbott began a double-blind, placebo-controlled Phase II trial to evaluate multiple dose strengths of ABT-450, ABT-333 or ABT-072 alone for 3 days followed by the addition of pegylated interferon and ribavirin for...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >